This is a multicenter pilot randomized controlled trial, with an active control condition, of the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a cohort of survivors of acute lymphoblastic leukemia or brain tumor ages 8-16 who are \> 1 year from the end of therapy.
Aged 8-16 years at time of screening.
History of diagnosis of acute lymphoblastic leukemia (ALL) or brain tumor (BT).
At least 1 year from completion of planned therapy and stable from a disease standpoint.
Participating child and caregiver are fluent in spoken English.
A history of photosensitive seizures.
A motor, visual, or auditory handicap that prevents computer use.
A mental health condition that precludes, or takes treatment precedence over, participation in the cognitive training.
Participants identified during the baseline assessment as having a full-scale IQ < 80, as estimated by WASI-II (Vocabulary and Matrix Reasoning), will not be randomized.
Children's National Research Institute
Lead sponsor
St. Jude Children's Research Hospital
Collaborator
Children's Hospital of Philadelphia
Collaborator
George Washington University
Collaborator
National Cancer Institute (NCI)
Collaborator